Format

Send to

Choose Destination
Infect Dis Ther. 2019 Sep;8(3):445-452. doi: 10.1007/s40121-019-0255-0. Epub 2019 Aug 1.

Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials.

Author information

1
Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.
2
Department of Surgery, Baystate Medical Center, Springfield, MA, USA.
3
Theravance Biopharma US, Inc., South San Francisco, CA, USA.
4
Theravance Biopharma US, Inc., South San Francisco, CA, USA. cbarnes@sprucebiosicences.com.

Abstract

INTRODUCTION:

The efficacy and safety of telavancin versus vancomycin in microbiologically evaluable patients with hospital-acquired or ventilator-associated pneumonia (HAP/VAP) caused by Staphylococcus aureus with vancomycin minimum inhibitory concentration (MIC) ≥ 1.0 µg/mL was analyzed using data derived from previously reported Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia (ATTAIN) trials.

METHODS:

This post hoc subgroup analysis of two randomized, double-blind, comparator-controlled, parallel-group phase 3 trials conducted at 274 sites in 38 countries included 194 microbiologically evaluable patients with HAP/VAP caused by monomicrobial S. aureus with vancomycin MIC ≥ 1.0 µg/mL. Patients received intravenous telavancin (10 mg/kg every 24 h) or intravenous vancomycin (1 g every 12 h with site-specific modifications) for 7-21 days. Efficacy was assessed by clinical cure, defined as improvement or non-progression of radiographic findings at end of treatment and resolution of pneumonia signs and symptoms at follow-up/test-of-cure visits, and survival 28 days post-randomization. Safety was assessed from categorical shifts in creatinine clearance during therapy and adverse events (AEs).

RESULTS:

Clinical cure rates were numerically greater following telavancin versus vancomycin treatment overall (85.4% vs. 74.3%; treatment difference [95% confidence interval (CI)], 11.1% [- 0.002%, 22.2%]) and in patients aged ≥ 65 years (81.6% vs. 66.2%; treatment difference [95% CI], 15.5% [- 0.9%, 30.2%]) patients with VAP (92.3% vs. 47.6%; treatment difference [95% CI], 44.7% [18.1%, 64.9%]), and patients with baseline Acute Physiology And Chronic Health Evaluation II score ≥ 20 (71.4% vs. 55.6%; treatment difference [95% CI], 15.9% [- 11.7%, 40.5%]). Renal function declined in 7 (7.9%) patients receiving telavancin and 6 (5.7%) patients receiving vancomycin. Survival proportion was numerically higher (85.2% vs. 80.2%; treatment difference [95% CI], 5.0% [- 5.8%, 15.8%]) and AEs were comparable in patients treated with telavancin versus vancomycin.

CONCLUSION:

Telavancin is an alternative to vancomycin for HAP/VAP caused by S. aureus with vancomycin MIC ≥ 1 µg/mL.

FUNDING:

Theravance Biopharma R&D, Inc., South San Francisco, CA, USA.

KEYWORDS:

Hospital-acquired pneumonia; MRSA; Staphylococcus aureus; Telavancin; Vancomycin; Ventilator-associated pneumonia

PMID:
31372837
DOI:
10.1007/s40121-019-0255-0

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center